NEU Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 13.88%

Insider Buying (Last 12 Months): A$59,950.00

Insider Selling (Last 12 Months): A$15,275,000.00

Neuren Pharmaceuticals Insider Trading History Chart

Neuren Pharmaceuticals Share Price & Price History

A^$0.00

+0.30 (1.20%)

As of 05/13/2020 01:00 AM ET

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Neuren Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/13/2023	Joseph(Joe) Basile	Insider	Buy	5,000	A$11.99	A$59,950.00
6/14/2023	Trevor Scott	Insider	Sell	1,175,000	A$13.00	A$15,275,000.00
10/18/2021	Dianne Angus	Insider	Buy	30,000	A$1.98	A$59,310.00
10/8/2021	Patrick Davies	Insider	Buy	14,634	A$2.05	A$29,999.70
6/24/2021	Patrick Davies	Insider	Buy	43,694	A$1.40	A$61,171.60
6/15/2021	Jonathan (Jon) Pilcher	Insider	Buy	19,039	A$1.31	A$24,998.21

How to camouflage a factory of 53,000 workers

From Stansberry Research | Ad

"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."

Get the full story here.

SEC Filings (Institutional Ownership Changes) for Neuren Pharmaceuticals (ASX:NEU)

16.07% of Neuren Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

57,935 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

Who are the company insiders with the largest holdings of Neuren Pharmaceuticals?: Neuren Pharmaceuticals' top insider investors include:
Joseph(Joe) Basile (Insider)
Trevor Scott (Insider)
Learn More about top insider investors at Neuren Pharmaceuticals.